ES2038664T3 - Briostatinas. - Google Patents

Briostatinas.

Info

Publication number
ES2038664T3
ES2038664T3 ES198787306552T ES87306552T ES2038664T3 ES 2038664 T3 ES2038664 T3 ES 2038664T3 ES 198787306552 T ES198787306552 T ES 198787306552T ES 87306552 T ES87306552 T ES 87306552T ES 2038664 T3 ES2038664 T3 ES 2038664T3
Authority
ES
Spain
Prior art keywords
bryostatin
briostatinas
linneaeus
bryozoan
phylum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787306552T
Other languages
English (en)
Inventor
George R. Pettit
Cherry L. Herald
Yoshiaki Kamano
John E. Leet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona State University ASU
Original Assignee
Arizona State University ASU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona State University ASU filed Critical Arizona State University ASU
Application granted granted Critical
Publication of ES2038664T3 publication Critical patent/ES2038664T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Vending Machines For Individual Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

NUEVOS AGENTES ANTIONEOPLASTICOS Y EXCEPCIONALMENTE POTENTES DENOMINADOS BRIOESTATINA 9, BRIOESTATINA 10, BRIOESTATINA 11, BRIOESTATINA 12 Y BRIOESTATINA 13 QUE SE HAN SEPARADO DEL ANIMAL MARINO BUGULA NERITINA (LINNEAEUS) (BRYOZOAN PHYLUM) Y LAS ESTRUCTURAS IDENTIFICADAS. CADA UNA DE ELLAS TIENE UNA ACTIVIDAD ANTINEOPLASTICA SIGNIFICATIVA.
ES198787306552T 1986-07-28 1987-07-24 Briostatinas. Expired - Lifetime ES2038664T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/889,946 US4833257A (en) 1986-07-28 1986-07-28 Compositions of matter and methods of using same

Publications (1)

Publication Number Publication Date
ES2038664T3 true ES2038664T3 (es) 1993-08-01

Family

ID=25396026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787306552T Expired - Lifetime ES2038664T3 (es) 1986-07-28 1987-07-24 Briostatinas.

Country Status (8)

Country Link
US (1) US4833257A (es)
EP (1) EP0264173B1 (es)
JP (1) JP2626889B2 (es)
AT (1) ATE71627T1 (es)
CA (1) CA1305476C (es)
DE (1) DE3776063D1 (es)
ES (1) ES2038664T3 (es)
GR (1) GR3004061T3 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256646A (en) * 1990-07-27 1993-10-26 Bristol-Myers Squibb Company Antiviral antibiotic BU-4224V
US5072004A (en) * 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
US5436400A (en) * 1993-01-19 1995-07-25 Arizona Board Of Regents Isolation and structure of spongistatin 1
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5478861A (en) * 1994-02-18 1995-12-26 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
US5684036A (en) * 1994-02-18 1997-11-04 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
US6060505A (en) * 1996-03-20 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of treating cancer using C-26 modified bryostatin
US7256286B2 (en) * 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
CA2393026A1 (en) 1999-11-30 2001-06-07 Paul A. Wender Bryostatin analogues, synthetic methods and uses
AU2001284364B2 (en) * 2000-07-31 2006-09-28 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
DE60229371D1 (de) * 2001-05-02 2008-11-27 Brni Neurosciences Inst Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
WO2003093275A1 (en) * 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill A bryostatin composition
EP1511477A4 (en) * 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS
AU2003281214A1 (en) * 2002-07-02 2004-01-23 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPAlpha SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
EP1567142A4 (en) * 2002-11-20 2005-12-14 Errant Gene Therapeutics Llc TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS
JP4668902B2 (ja) 2003-08-07 2011-04-13 ヒーラー リミテッド 創傷治癒を促進するための薬剤組成物及び方法
TW201207390A (en) * 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
CA2587013A1 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2617003A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
EP2452686A3 (en) * 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
JP2009544753A (ja) 2006-07-28 2009-12-17 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 細胞成長、シナプスリモデリング及び長期記憶の固定を刺激する方法
KR20090120480A (ko) 2007-02-09 2009-11-24 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 허혈/뇌졸중-유도된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련된 물질의 치료학적 효과
EP2959914A1 (en) 2007-02-09 2015-12-30 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryologs on head trauma-induced memory impairment and brain injury
EP2185184A2 (en) * 2007-07-30 2010-05-19 HealOr Ltd. Pharmaceutical composition for treating wounds and related methods
RU2011138183A (ru) * 2009-02-24 2013-04-10 Хилор Лтд. Висфатиновые терапевтические средства для лечения акне и других состояний
CA2786854A1 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
WO2012006525A2 (en) 2010-07-08 2012-01-12 Alkon Daniel L Pkc activators and anticoagulant in regimen for treating stroke
JP6062362B2 (ja) 2010-08-19 2017-01-18 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｐｋｃ活性化剤を使用した、異常な樹状突起棘に関連した認知障害の治療
WO2013071282A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
CN109331013B (zh) * 2012-11-27 2022-02-01 阿菲欧斯公司 苔藓素组合物、其制备方法和用途
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
US20180217163A1 (en) 2015-05-11 2018-08-02 Daniel L. Alkon Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
US11629167B2 (en) 2017-11-09 2023-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Betulastatin compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
JPS60174418A (ja) * 1984-02-18 1985-09-07 Ishikawajima Harima Heavy Ind Co Ltd 下水あるいはし尿汚泥等の流動層式焼却装置
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8

Also Published As

Publication number Publication date
JP2626889B2 (ja) 1997-07-02
EP0264173B1 (en) 1992-01-15
GR3004061T3 (es) 1993-03-31
US4833257A (en) 1989-05-23
EP0264173A3 (en) 1988-07-13
JPS63183585A (ja) 1988-07-28
DE3776063D1 (en) 1992-02-27
EP0264173A2 (en) 1988-04-20
CA1305476C (en) 1992-07-21
ATE71627T1 (de) 1992-02-15

Similar Documents

Publication Publication Date Title
ES2038664T3 (es) Briostatinas.
DK172089D0 (da) 1,3-dioxolanderivater samt fremgangsmaade til fremstilling deraf
NO20004978D0 (no) Semi-syntetiske ecteinascidiner
FI890916A0 (fi) Anordning foer befraemjande av periodisk ledroerelse och muskelaktivitet.
FI930977A (fi) Taxanderivat, deras framstaellning och onkologiska anvaendning
MC1772A1 (fr) Derives de la quinoleine
ES2015047B3 (es) Nuevos derivados de 18-fenilestrano.
ES544752A0 (es) Un procedimiento para la preparacion de carbapenems.
FI892222A0 (fi) Peptidalkoholer med antikoagulantverkan.
DE3777590D1 (de) 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m-phenylene-pgi2-derivate.
TR23373A (tr) N'-suebstitueye-n,n'-diasilhidrazinlerin 5 ueyeli heterosiklik tuerevleri
ES2060050T3 (es) Beta-tioacrilamidas s-sustituidas y su uso como microbicidas.
WO1988003922A3 (en) Thiophenesulfonamide herbicides
FI934468A0 (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytesmellanprodukter
FR2597105B1 (fr) Derives antibiotiques de la famille des 20-0-acyl-19,20-enolmacrolides
SU1786802A1 (ru) 2,4-ДИМЕТИЛ-9-ОКСИПИРИДО[1,2-a]ПИРИМИДИНИЙХЛОРИД, ОБЛАДАЮЩИЙ АНТИДЕПРЕССИВНОЙ АКТИВНОСТЬЮ
AR241135A2 (es) "derivados de n-triazinil-n-sulfamoilurea herbicidamente activos y formulacion herbicida que los contiene".
FI873000A (fi) Substituoituja 1,2,3-tiadiatsoli-4-tiolaatteja
SU1351063A1 (ru) Производные 2-тиазолзамещенного 5-нитрофурана, проявляющие антистафилококковую активность
SU1417444A1 (ru) 2,4-Дифенил-3(4-ацетокси-4-метилгексин-2-ил)-3-азабицикло [3,3,1]нонан-9-он, проявляющий противовоспалительную активность
LV5507A3 (lv) 4,5.-Dihidrooksazolu atvasinajumu iegusanas panemiens
SU1637248A1 (ru) Оксалат n-метил-n-пропаргил-(2-n',n'-диметиламинометилпиридил-3)-карбамата, обладающий антихолинэстеразной и миотической активностью
SU1489139A1 (ru) 3-Изобутил-1-(4-тиоцианатофенил)-5-фенил-Δ-пиразолин, проявляющий противовоспалительную активность

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 264173

Country of ref document: ES